Treatment efficacy for Sézary syndrome: an international, multi-centre, comparative study of current systemic therapies

2021 ◽  
Vol 156 ◽  
pp. S20
Author(s):  
Belinda A Campbell ◽  
Gabor Dobos ◽  
Zahra Haider ◽  
Martine Bagot ◽  
H. Miles Prince ◽  
...  
Keyword(s):  
Comparative Study ◽  
Treatment Efficacy ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Systemic Therapies

scholarly journals Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy

Blood ◽  
2015 ◽  
Vol 125 (1) ◽  
pp. 71-81 ◽  
Author(s):  
Charlotte F. M. Hughes ◽  
Amit Khot ◽  
Christopher McCormack ◽  
Stephen Lade ◽  
David A. Westerman ◽  
...  
Keyword(s):  
Comparative Study ◽  
Disease Control ◽  
Median Time ◽  
Mycosis Fungoides ◽  
Systemic Therapy ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Key Points

Key Points Chemotherapy results in a short median time to next treatment in patients with mycosis fungoides/Sézary syndrome. α-interferon achieves a superior time to next treatment compared with chemotherapy, regardless of stage.

A comparative outcome analysis comparing systemic therapies in Mycosis Fungoides and Sezary Syndrome.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 7571-7571
Author(s):  
Walter Hanel ◽  
Robert Briski ◽  
Charles W Ross ◽  
Thomas F Anderson ◽  
Mark S Kaminski ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Outcome Analysis ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Systemic Therapies

scholarly journals New systemic treatment options in mycosis fungoides and Sézary syndrome

2020 ◽  
Vol 13 (3) ◽  
pp. 280-284
Author(s):  
Magdalena Seidl-Philipp ◽  
Van Anh Nguyen
Keyword(s):  
Mycosis Fungoides ◽  
Histone Deacetylase Inhibitors ◽  
Early Stage ◽  
Treatment Options ◽  
Progression Free Survival ◽  
Good Prognosis ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Allogenic Stem Cell Transplantation ◽  
Systemic Therapies

Summary Cutaneous T cell lymphomas (CTCL) are a heterogeneous group of rare non-Hodgkin lymphomas. The most common type of CTCL is Mycosis fungoides (MF). Much less common but clinically and histopathologically related to MF is Sézary syndrome (SS). CTCL are incurable and associated with a reduced quality of life. While early stage MF has a good prognosis and is usually treated with skin directed therapies, advanced-stages require systemic therapies, including retinoids, interferon, cytotoxic chemotherapeutic drugs, low-dose methotrexate, histone deacetylase inhibitors and alemtuzumab. However, relapses are frequent and long-term remissions are achieved only in few cases, e.g. with allogenic stem cell transplantation. In recent years, new therapeutic options have evolved by the approval of brentuximab vedotin and mogamulizumab. Both recently approved therapies demonstrated superiority with regard to overall response rate and progression free survival over traditional systemic therapies. Other promising treatments such as lacutamab and PD-1/L-1 inhibitors are in the pipeline, and more therapeutic agents are currently investigated in clinical trials.

Mycosis fungoides? Sezary syndrome

1970 ◽  
Vol 101 (2) ◽  
pp. 244-246 ◽  
Author(s):  
H. H. Roenigk
Keyword(s):  
Mycosis Fungoides ◽  
Sézary Syndrome ◽  
Sezary Syndrome
Sign in / Sign up

Export Citation Format

Share Document